Skip to main content
TipRanks
Go Ultimate75% OFF

RPG Life Sciences Limited (RPGLIFE) AI Stock Analysis

2 Followers
IN:RPGLIFE

RPG Life Sciences Limited

(NSE:RPGLIFE)

Select Model
Rating:62Neutral
Price Target:INR 2,727.00â–²(6.88% Upside)
Action:downgraded
Date:10/31/26

The score is primarily supported by strong financial flexibility from a conservative balance sheet, but it is meaningfully constrained by recent profitability and cash-flow deterioration. Technically, the stock is below key short-to-medium moving averages, and valuation is relatively expensive (high P/E with a modest yield), limiting upside without improved execution.

Positive Factors
Conservative Balance SheetA conservatively positioned balance sheet gives RPG Life Sciences substantial financial flexibility during operating volatility. Low leverage reduces interest and refinancing pressure, while supporting continued investment in products, manufacturing capacity, and domestic commercial operations over the coming quarters.
Negative Factors
Recent Margin CompressionThe sharp FY2026 margin decline weakens confidence in near-term earnings durability and shows that revenue growth has not translated consistently into profit growth. Unless profitability recovers, reduced operating leverage could constrain reinvestment and limit earnings progression.

RPG Life Sciences Limited (RPGLIFE) vs. iShares MSCI India ETF (INDA)

-30%-20%-10%0%10%20%30%40%IN:RPGLIFE+12.28%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 42.20B
Dividend Yield
0.94%
Average Volume (3M)
1,376
Price to Earnings (P/E)
38.0
Beta (1Y)
0.80
Revenue Growth
14.68%
EPS Growth
-49.22%
Country
India
Employees
1,366
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

RPG Life Sciences Limited Business Overview & Revenue Model

Company Description

RPG Life Sciences Limited operates as a fully integrated pharmaceutical enterprise, engaged in the development, production, and commercialization of branded drug formulations, generic medications, and synthetic active pharmaceutical ingredients (APIs...

RPG Life Sciences Limited Financial Statement Overview

Summary

Strong balance sheet strength (very low leverage and solid ROE history) supports a high-quality profile, but the score is held back by recent margin compression and a notable deterioration in cash-flow conversion, with FY2026 free cash flow turning slightly negative.

Income Statement

78Positive

Balance Sheet

92Very Positive

Cash Flow

58Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue7.64B7.08B6.53B5.77B5.09B4.37B
Gross Profit3.72B2.92B4.39B3.93B1.70B2.87B
EBITDA1.74B1.77B1.60B1.36B1.08B902.40M
Net Income1.09B1.15B1.83B876.60M676.40M514.80M
Balance Sheet
Total Assets11.16B7.93B6.58B5.13B4.19B3.45B
Cash, Cash Equivalents and Short-Term Investments2.93B2.75B2.66B1.26B1.15B698.00M
Total Debt264.40M200.00M00100.00K9.40M
Total Liabilities2.50B1.88B1.27B1.38B1.12B888.40M
Stockholders Equity6.87B6.05B5.31B3.75B3.08B2.56B
Cash Flow
Free Cash Flow0-800.00K418.30M251.30M580.90M408.00M
Operating Cash Flow0652.80M778.60M943.60M908.20M647.50M
Investing Cash Flow0761.70M-418.00M-791.50M-1.06B-346.60M
Financing Cash Flow0-196.90M-270.80M-203.10M-171.20M-135.10M

RPG Life Sciences Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price2551.45

Price Trends

50DMA2770.05Negative
100DMA2712.30Negative
200DMA2374.59Positive

Market Momentum

MACD-67.18Positive
RSI41.98Neutral
STOCH30.56Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:RPGLIFE, the sentiment is Negative. The current price of 2551.45 is below the 20-day moving average (MA) of 2694.37, below the 50-day MA of 2770.05, and above the 200-day MA of 2374.59, indicating a neutral trend. The MACD of -67.18 indicates Positive momentum. The RSI at 41.98 is Neutral, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:RPGLIFE.

RPG Life Sciences Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:RPGLIFE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:IOLCPIN:IOLCP72OutperformINR 59.18B29.14―0.50%26.76%75.41%
IN:BLISSGVSIN:BLISSGVS65NeutralINR 71.56B44.52―0.22%24.87%46.37%
IN:RPGLIFEIN:RPGLIFE62NeutralINR 42.20B38.01―0.94%14.68%-49.22%
IN:HIKALIN:HIKAL61NeutralINR 27.45B-556.17―0.27%8.93%-149.51%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:UNICHEMLABIN:UNICHEMLAB51NeutralINR 35.07B10.36――6.44%283.10%
IN:SOLARAIN:SOLARA50NeutralINR 33.20B89.33――27.30%456.80%

* General Sector Average

Performance Comparison

0%100%200%300%IN:RPGLIFEIN:BLISSGVSIN:HIKALIN:IOLCPIN:SOLARAIN:UNICHEMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:RPGLIFE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:RPGLIFERPG Life Sciences Limited2551.45260.8311.39%
IN:BLISSGVSBliss Gvs Pharma Limited673.00510.22313.45%
IN:HIKALHikal Limited222.60-10.59-4.54%
IN:IOLCPIOL Chemicals & Pharmaceuticals Ltd.201.60107.48114.19%
IN:SOLARASolara Active Pharma Sciences Ltd.690.60115.4520.07%
IN:UNICHEMLABUnichem Laboratories Limited498.0521.604.53%

RPG Life Sciences Limited Corporate Events

RPG Life Sciences Files Investor Presentation on FY27 Q2 and H1 Results

Oct 29, 2026

RPG Life Sciences Limited has submitted an investor presentation to Indian stock exchanges detailing its unaudited financial results for the quarter and half year ended September 30, 2026. The disclosure underscores the company’s ongoing efforts to m...

RPG Life Sciences Subsidiary RPG Active Pharma to Merge Actis Generics

Sep 25, 2026

RPG Life Sciences has announced that the board of its subsidiary RPG Active Pharma Limited has approved a scheme of amalgamation to merge its wholly owned subsidiary Actis Generics Private Limited into RPG Active Pharma. The transaction is a related-...

RPG Life Sciences Completes Acquisition of Actis Generics

Sep 24, 2026

RPG Life Sciences Limited has completed the acquisition of Actis Generics Private Limited through its subsidiary RPG Active Pharma Limited, following a share purchase agreement signed on July 29, 2026. As of September 24, 2026, Actis Generics becomes...

RPG Life Sciences Completes Acquisition of API Business via Slump Sale

Sep 15, 2026

RPG Life Sciences has announced that its subsidiary RPG Active Pharma Limited has completed the business transfer agreement with Raghava Life Sciences Private Limited for the acquisition of active pharmaceutical ingredients and intermediates business...

RPG Life Sciences Posts Analyst Call Recording for Investor Access

Sep 4, 2026

RPG Life Sciences Limited has informed the stock exchanges that the recording and related details of its analyst and institutional investor call held on September 3, 2026 are now available on the company’s website for public access. The disclosure un...

RPG Life Sciences to Brief Investors on API Business in Scheduled Conference Call

Sep 3, 2026

RPG Life Sciences Limited has scheduled an analyst and institutional investor conference call to provide an update on its API business, with senior management, including the managing director and chief financial officer, set to address participants....

RPG Life Sciences Circulates Investor Presentation on Active Pharma Transaction

Sep 2, 2026

RPG Life Sciences Limited has notified India’s major stock exchanges that it has prepared an investor presentation for analysts and institutional investors. The company, which operates in the pharmaceutical sector and is listed on NSE and BSE, contin...

RPG Life Sciences Cancels Scheduled Investor and Analyst Meet

Sep 1, 2026

RPG Life Sciences Limited has announced that its previously scheduled investors and analysts meeting, which was to be held on Wednesday, September 2, 2026, at 10:00 a.m., has been cancelled. The company informed the stock exchanges in compliance with...

RPG Life Sciences injects Rs 65.69 crore into wholly owned pharma subsidiary

Aug 14, 2026

RPG Life Sciences Limited has invested up to Rs 65.69 crore in its wholly owned subsidiary, RPG Active Pharma Limited through a rights issue of equity shares. Following the allotment of 21,89,535 shares on August 14, 2026, RPG Life Sciences’ sharehol...

RPG Life Sciences Completes Transfer of API Business to Subsidiary

Aug 14, 2026

RPG Life Sciences Limited has completed the transfer of its active pharmaceutical ingredients business to RPG Active Pharma Limited, a wholly owned subsidiary, under a business transfer agreement executed on a slump sale basis. The transaction, effec...

RPG Life Sciences Moves API Chief to Lead Subsidiary RPG Active Pharma

Aug 14, 2026

RPG Life Sciences Limited has announced a key change in its senior management, centered on its API operations and subsidiary governance. The move reflects the company’s practice of aligning leadership roles with its multi-entity pharmaceutical struct...

RPG Life Sciences to Join Emkay Confluence 2026 Investor Meet

Aug 10, 2026

RPG Life Sciences Limited has informed the stock exchanges that it will participate in the Emkay Confluence 2026, an analyst and institutional investors meet scheduled in Mumbai on August 13, 2026, starting at 9:00 a.m. IST. The session will be a phy...

RPG Life Sciences Discloses Retirement of Senior Sales and Marketing Executive

Jul 31, 2026

RPG Life Sciences Limited has announced that Mr. Samir Rane, Vice President, Sales & Marketing – Main Division, has retired upon attaining the age of superannuation and consequently ceased to be part of the company’s senior management. The change, ef...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026